IRLAB reports top-line results from Phase IIa study with IRL752

June 29, 2018

IRLAB reports that the clinical Phase IIa study with IRL752 has been completed according to plan. The primary study objectives have been met. After full data analysis, the next development step is a larger efficacy study with longer treatment times.

For more information, read the full press release here.